Biotheranostics, Inc. has announced new pivotal data on the Breast Cancer Index (BCI) being presented at the ASCO conference June 3, 2019 that further validates its ability to accurately predict which women with early-stage, hormone receptor positive (HR+) breast cancer will benefit from extended endocrine therapy. Findings from the Translational-aTTom study (Trans-aTTom) led by an international team of cancer researchers strengthen BCI clinical evidence as a predictive biomarker and highlight its utility in helping physicians determine 5 vs. 10-year endocrine treatment plans for their patients.

The Trans-aTTom study to date includes 1,822 patients treated in the aTTom trial, which randomized nearly 7,000 HR+ women to either stop or continue tamoxifen for 5 more years after completing at least 4 years of endocrine therapy. Data presented on 583 patients with N+ disease demonstrated that the Breast Cancer Index effectively stratified patients based on their response to extended endocrine therapy, identifying 49% of patients that showed a statistically significant benefit of 10.2% with 10 years of tamoxifen, and 51% of patients that did not show a statistically significant benefit from continued treatment. These data provide further validation and establish level 1B evidence for Breast Cancer Index as the only predictive biomarker for benefit from extended endocrine therapy in early-stage, HR+ breast cancer.

A significant dilemma in early-stage, HR+ breast cancer is determining the optimal duration of endocrine therapy to reduce the ongoing risk of distant recurrence. For breast cancer patients on endocrine therapy, the side effects and toxicities associated with treatment often have a severe impact on health and quality of life (e.g., osteoporosis, endometrial cancer, blood clots, joint pain) For these women, weighing the health risks against the potential benefit of continuing endocrine therapy beyond 5 years is essential for individual treatment planning. Thus, identifying women for whom extending endocrine therapy helps reduce their risk of recurrence is important to help decrease their anxiety, increase their satisfaction and comfort with their treatment decision, and potentially enable them to comply effectively with their treatment plan. Breast Cancer Index is the only test validated to predict which patients will benefit from endocrine therapy beyond 5 years, helping inform the decision of 5 vs 10 years of endocrine therapy. No other genomic tests or clinicopathologic factors have demonstrated the ability to predict extended endocrine therapy benefit.

Catherine Schnabel, Ph.D., Chief Scientific Officer, Biotheranostics, said, “Results from the Trans-aTTom study add to the growing body of evidence that BCI accurately identifies which early-stage HR+ patients are associated with better outcomes and preferential response to extended endocrine therapy. Clinicians may use BCI to personalize their approach and provide validated genomic information to help patients weigh the risks and benefits of prolonging their endocrine treatment.”

Don Hardison, Biotheranostics’ President, and CEO added, “We are very pleased with results from the Trans-aTTom validation study. It provides further validation that Breast Cancer Index is the only predictive biomarker for extended endocrine therapy in early-stage, HR+ breast cancer. We are committed to ensuring that every breast cancer patient and her physician have information to help determine the best approach to individualize treatment.”

Latest news

Vertos mild® Patients Demonstrate Durable 5 Year Outcomes
May 18, 2021

Most Minimally Invasive Lumbar Decompression (mild®) providers are very familiar with the 1-year study conducted by Nagy Mekhail, MD, PhD […]

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021

Saint-Herblain (France), May 6, 2021  – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]

Valneva Initiates Phase 3 Clinical Trial for its Inactivated,
Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 29, 2021

Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic […]

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 6, 2021

April 6, 2021 VLA2001 was well tolerated with no safety concerns identified In the high dose group : IgG seroconversion […]

eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021

eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]

Hologic announces acquisition of Biotheranostics
January 5, 2021

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has agreed to acquire Biotheranostics, Inc., […]

MVM invests in GT Medical
November 23, 2020

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has […]

Valneva announces major COVID-19 vaccine partnership with UK government
September 14, 2020

– UK Government has secured supply of 60 million doses at a cost of €470 million with options over another […]

MVM invests in Paragon 28
August 15, 2020

Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing. The […]

Valneva confirms participation in UK government COVID-19 vaccine response program
July 20, 2020

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed its participation in […]